Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia
Introduction and Aims: Acute myeloid leukemia (AML) in adults has poor prognosis. The epidemiologic profile of patients varies greatly in different geographic locations and so do the cytogenetic abnormalities and the FAB subtype of the AML. We intended to study the clinical profile, cytogenetics, an...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and therapeutics 2020-01, Vol.16 (1), p.18-22 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 22 |
|---|---|
| container_issue | 1 |
| container_start_page | 18 |
| container_title | Journal of cancer research and therapeutics |
| container_volume | 16 |
| creator | Namratha Udupa, M Babu, K Suresh Babu, M Lakshmaiah, K Lokanatha, D Jacob, A Lokesh, K Rajeev, L Rudresh, A Devi, Lakshmi |
| description | Introduction and Aims: Acute myeloid leukemia (AML) in adults has poor prognosis. The epidemiologic profile of patients varies greatly in different geographic locations and so do the cytogenetic abnormalities and the FAB subtype of the AML. We intended to study the clinical profile, cytogenetics, and outcomes with standard of care treatment on our population in India.
Methods: This was a retrospective study with systematic review of 203 case records. Primary objectives were to know the demographic profile of AML, prevalence of various FAB subtypes, cytogenetic abnormalities, and treatment outcomes at our center, which is a referral center of oncology. Two treatment outcomes considered in study for patients of AML were achievement of remission status of the bone marrow postintensive induction chemotherapy and sustenance of the remission for 6 months, once remission is achieved. Secondary objective was to study these outcomes in non-M3 AML in relation to cytogenetics.
Results: Median age was 39 years. The most common FAB subtype observed was AML M2. About 65.6% patients achieved complete remission (CR), and 42.4% patients could sustain it for next 6 months. Cytogenetics correlated with prognosis but not age.
Conclusions: Our population differs from the Western population regarding lower age, lower prevalence of adverse cytogenetics, and higher prevalence of favorable cytogenetic abnormalities. Cytogenetics had a good correlation with CR rates after chemotherapy as well as its sustenance. |
| doi_str_mv | 10.4103/jcrt.JCRT_1162_16 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2398163355</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A623244112</galeid><sourcerecordid>A623244112</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541l-7ea673a62fdd9e6134db26ae52b08c2e97bc73ed7b18dc2b508303dc1b2e0e823</originalsourceid><addsrcrecordid>eNp1kktv1DAUhS0EokPhB7BBltiwaAb7OnGcZRlRHqqEhNq15dg3VWacuNiORvPvSTQtLw3ywpvvHN97jgl5zdm65Ey839qY118332805xI0l0_IijeNKkou1FOyYk0tCl4qOCMvUtoyVtUA6jk5EyAkSFauyO3G92Nvjaf3MXS9xwtqDznc4Yi5t4ma0dEc0eQBx0zDlG0YMNHQUeMmn6mxU0Y6HNCH3lGP0w6H3rwkzzrjE756uM_J7dXHm83n4vrbpy-by-vCViX3RY1G1sJI6JxrUHJRuhakwQpapixgU7e2Fujqlitnoa2YEkw4y1tAhgrEOXl39J2H_zFhynrok0XvzYhhShpEo7gUoqpm9O0_6DZMcZyn01AyBgqglr-pO-NR92MXcjR2MdWXEgSUJefLs8UJasksGh9GXHL8m1-f4Ofj5rDsSQE_CmwMKUXs9H3sBxMPmjO9VK-X6vWf1c-aNw8LTu2A7pfisesZ-HAE9sFnjGnnpz1GPbO7Mez_76y50o-_RPwEdIfAiA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2400282276</pqid></control><display><type>article</type><title>Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia</title><source>MEDLINE</source><source>Medknow Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Namratha Udupa, M ; Babu, K ; Suresh Babu, M ; Lakshmaiah, K ; Lokanatha, D ; Jacob, A ; Lokesh, K ; Rajeev, L ; Rudresh, A ; Devi, Lakshmi</creator><creatorcontrib>Namratha Udupa, M ; Babu, K ; Suresh Babu, M ; Lakshmaiah, K ; Lokanatha, D ; Jacob, A ; Lokesh, K ; Rajeev, L ; Rudresh, A ; Devi, Lakshmi</creatorcontrib><description>Introduction and Aims: Acute myeloid leukemia (AML) in adults has poor prognosis. The epidemiologic profile of patients varies greatly in different geographic locations and so do the cytogenetic abnormalities and the FAB subtype of the AML. We intended to study the clinical profile, cytogenetics, and outcomes with standard of care treatment on our population in India.
Methods: This was a retrospective study with systematic review of 203 case records. Primary objectives were to know the demographic profile of AML, prevalence of various FAB subtypes, cytogenetic abnormalities, and treatment outcomes at our center, which is a referral center of oncology. Two treatment outcomes considered in study for patients of AML were achievement of remission status of the bone marrow postintensive induction chemotherapy and sustenance of the remission for 6 months, once remission is achieved. Secondary objective was to study these outcomes in non-M3 AML in relation to cytogenetics.
Results: Median age was 39 years. The most common FAB subtype observed was AML M2. About 65.6% patients achieved complete remission (CR), and 42.4% patients could sustain it for next 6 months. Cytogenetics correlated with prognosis but not age.
Conclusions: Our population differs from the Western population regarding lower age, lower prevalence of adverse cytogenetics, and higher prevalence of favorable cytogenetic abnormalities. Cytogenetics had a good correlation with CR rates after chemotherapy as well as its sustenance.</description><identifier>ISSN: 0973-1482</identifier><identifier>EISSN: 1998-4138</identifier><identifier>DOI: 10.4103/jcrt.JCRT_1162_16</identifier><identifier>PMID: 32362604</identifier><language>eng</language><publisher>India: Wolters Kluwer India Pvt. Ltd</publisher><subject>Acute myelocytic leukemia ; Adolescent ; Adult ; Adults ; Age ; Aged ; Aged, 80 and over ; Bone marrow ; Bone Marrow - pathology ; Cancer genetics ; Chemotherapy ; Chromosome Aberrations ; Clinical outcomes ; Cytogenetics ; Decitabine ; Disease ; Female ; Fever ; Humans ; India ; Induction Chemotherapy - methods ; Karyotyping - methods ; Leukemia ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - pathology ; Male ; Medical prognosis ; Middle Aged ; Myeloid leukemia ; Patient outcomes ; Population ; Prognosis ; Retrospective Studies ; Treatment Outcome ; Young Adult</subject><ispartof>Journal of cancer research and therapeutics, 2020-01, Vol.16 (1), p.18-22</ispartof><rights>COPYRIGHT 2020 Medknow Publications and Media Pvt. Ltd.</rights><rights>2020. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541l-7ea673a62fdd9e6134db26ae52b08c2e97bc73ed7b18dc2b508303dc1b2e0e823</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27458,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32362604$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Namratha Udupa, M</creatorcontrib><creatorcontrib>Babu, K</creatorcontrib><creatorcontrib>Suresh Babu, M</creatorcontrib><creatorcontrib>Lakshmaiah, K</creatorcontrib><creatorcontrib>Lokanatha, D</creatorcontrib><creatorcontrib>Jacob, A</creatorcontrib><creatorcontrib>Lokesh, K</creatorcontrib><creatorcontrib>Rajeev, L</creatorcontrib><creatorcontrib>Rudresh, A</creatorcontrib><creatorcontrib>Devi, Lakshmi</creatorcontrib><title>Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia</title><title>Journal of cancer research and therapeutics</title><addtitle>J Cancer Res Ther</addtitle><description>Introduction and Aims: Acute myeloid leukemia (AML) in adults has poor prognosis. The epidemiologic profile of patients varies greatly in different geographic locations and so do the cytogenetic abnormalities and the FAB subtype of the AML. We intended to study the clinical profile, cytogenetics, and outcomes with standard of care treatment on our population in India.
Methods: This was a retrospective study with systematic review of 203 case records. Primary objectives were to know the demographic profile of AML, prevalence of various FAB subtypes, cytogenetic abnormalities, and treatment outcomes at our center, which is a referral center of oncology. Two treatment outcomes considered in study for patients of AML were achievement of remission status of the bone marrow postintensive induction chemotherapy and sustenance of the remission for 6 months, once remission is achieved. Secondary objective was to study these outcomes in non-M3 AML in relation to cytogenetics.
Results: Median age was 39 years. The most common FAB subtype observed was AML M2. About 65.6% patients achieved complete remission (CR), and 42.4% patients could sustain it for next 6 months. Cytogenetics correlated with prognosis but not age.
Conclusions: Our population differs from the Western population regarding lower age, lower prevalence of adverse cytogenetics, and higher prevalence of favorable cytogenetic abnormalities. Cytogenetics had a good correlation with CR rates after chemotherapy as well as its sustenance.</description><subject>Acute myelocytic leukemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Adults</subject><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bone marrow</subject><subject>Bone Marrow - pathology</subject><subject>Cancer genetics</subject><subject>Chemotherapy</subject><subject>Chromosome Aberrations</subject><subject>Clinical outcomes</subject><subject>Cytogenetics</subject><subject>Decitabine</subject><subject>Disease</subject><subject>Female</subject><subject>Fever</subject><subject>Humans</subject><subject>India</subject><subject>Induction Chemotherapy - methods</subject><subject>Karyotyping - methods</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Myeloid leukemia</subject><subject>Patient outcomes</subject><subject>Population</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0973-1482</issn><issn>1998-4138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kktv1DAUhS0EokPhB7BBltiwaAb7OnGcZRlRHqqEhNq15dg3VWacuNiORvPvSTQtLw3ywpvvHN97jgl5zdm65Ey839qY118332805xI0l0_IijeNKkou1FOyYk0tCl4qOCMvUtoyVtUA6jk5EyAkSFauyO3G92Nvjaf3MXS9xwtqDznc4Yi5t4ma0dEc0eQBx0zDlG0YMNHQUeMmn6mxU0Y6HNCH3lGP0w6H3rwkzzrjE756uM_J7dXHm83n4vrbpy-by-vCViX3RY1G1sJI6JxrUHJRuhakwQpapixgU7e2Fujqlitnoa2YEkw4y1tAhgrEOXl39J2H_zFhynrok0XvzYhhShpEo7gUoqpm9O0_6DZMcZyn01AyBgqglr-pO-NR92MXcjR2MdWXEgSUJefLs8UJasksGh9GXHL8m1-f4Ofj5rDsSQE_CmwMKUXs9H3sBxMPmjO9VK-X6vWf1c-aNw8LTu2A7pfisesZ-HAE9sFnjGnnpz1GPbO7Mez_76y50o-_RPwEdIfAiA</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Namratha Udupa, M</creator><creator>Babu, K</creator><creator>Suresh Babu, M</creator><creator>Lakshmaiah, K</creator><creator>Lokanatha, D</creator><creator>Jacob, A</creator><creator>Lokesh, K</creator><creator>Rajeev, L</creator><creator>Rudresh, A</creator><creator>Devi, Lakshmi</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20200101</creationdate><title>Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia</title><author>Namratha Udupa, M ; Babu, K ; Suresh Babu, M ; Lakshmaiah, K ; Lokanatha, D ; Jacob, A ; Lokesh, K ; Rajeev, L ; Rudresh, A ; Devi, Lakshmi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541l-7ea673a62fdd9e6134db26ae52b08c2e97bc73ed7b18dc2b508303dc1b2e0e823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acute myelocytic leukemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Adults</topic><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bone marrow</topic><topic>Bone Marrow - pathology</topic><topic>Cancer genetics</topic><topic>Chemotherapy</topic><topic>Chromosome Aberrations</topic><topic>Clinical outcomes</topic><topic>Cytogenetics</topic><topic>Decitabine</topic><topic>Disease</topic><topic>Female</topic><topic>Fever</topic><topic>Humans</topic><topic>India</topic><topic>Induction Chemotherapy - methods</topic><topic>Karyotyping - methods</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Myeloid leukemia</topic><topic>Patient outcomes</topic><topic>Population</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Namratha Udupa, M</creatorcontrib><creatorcontrib>Babu, K</creatorcontrib><creatorcontrib>Suresh Babu, M</creatorcontrib><creatorcontrib>Lakshmaiah, K</creatorcontrib><creatorcontrib>Lokanatha, D</creatorcontrib><creatorcontrib>Jacob, A</creatorcontrib><creatorcontrib>Lokesh, K</creatorcontrib><creatorcontrib>Rajeev, L</creatorcontrib><creatorcontrib>Rudresh, A</creatorcontrib><creatorcontrib>Devi, Lakshmi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Namratha Udupa, M</au><au>Babu, K</au><au>Suresh Babu, M</au><au>Lakshmaiah, K</au><au>Lokanatha, D</au><au>Jacob, A</au><au>Lokesh, K</au><au>Rajeev, L</au><au>Rudresh, A</au><au>Devi, Lakshmi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia</atitle><jtitle>Journal of cancer research and therapeutics</jtitle><addtitle>J Cancer Res Ther</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>16</volume><issue>1</issue><spage>18</spage><epage>22</epage><pages>18-22</pages><issn>0973-1482</issn><eissn>1998-4138</eissn><abstract>Introduction and Aims: Acute myeloid leukemia (AML) in adults has poor prognosis. The epidemiologic profile of patients varies greatly in different geographic locations and so do the cytogenetic abnormalities and the FAB subtype of the AML. We intended to study the clinical profile, cytogenetics, and outcomes with standard of care treatment on our population in India.
Methods: This was a retrospective study with systematic review of 203 case records. Primary objectives were to know the demographic profile of AML, prevalence of various FAB subtypes, cytogenetic abnormalities, and treatment outcomes at our center, which is a referral center of oncology. Two treatment outcomes considered in study for patients of AML were achievement of remission status of the bone marrow postintensive induction chemotherapy and sustenance of the remission for 6 months, once remission is achieved. Secondary objective was to study these outcomes in non-M3 AML in relation to cytogenetics.
Results: Median age was 39 years. The most common FAB subtype observed was AML M2. About 65.6% patients achieved complete remission (CR), and 42.4% patients could sustain it for next 6 months. Cytogenetics correlated with prognosis but not age.
Conclusions: Our population differs from the Western population regarding lower age, lower prevalence of adverse cytogenetics, and higher prevalence of favorable cytogenetic abnormalities. Cytogenetics had a good correlation with CR rates after chemotherapy as well as its sustenance.</abstract><cop>India</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><pmid>32362604</pmid><doi>10.4103/jcrt.JCRT_1162_16</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0973-1482 |
| ispartof | Journal of cancer research and therapeutics, 2020-01, Vol.16 (1), p.18-22 |
| issn | 0973-1482 1998-4138 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2398163355 |
| source | MEDLINE; Medknow Open Access Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Acute myelocytic leukemia Adolescent Adult Adults Age Aged Aged, 80 and over Bone marrow Bone Marrow - pathology Cancer genetics Chemotherapy Chromosome Aberrations Clinical outcomes Cytogenetics Decitabine Disease Female Fever Humans India Induction Chemotherapy - methods Karyotyping - methods Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - pathology Male Medical prognosis Middle Aged Myeloid leukemia Patient outcomes Population Prognosis Retrospective Studies Treatment Outcome Young Adult |
| title | Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A36%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20profile,%20cytogenetics%20and%20treatment%20outcomes%20of%20adult%20acute%20myeloid%20leukemia&rft.jtitle=Journal%20of%20cancer%20research%20and%20therapeutics&rft.au=Namratha%20Udupa,%20M&rft.date=2020-01-01&rft.volume=16&rft.issue=1&rft.spage=18&rft.epage=22&rft.pages=18-22&rft.issn=0973-1482&rft.eissn=1998-4138&rft_id=info:doi/10.4103/jcrt.JCRT_1162_16&rft_dat=%3Cgale_proqu%3EA623244112%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2400282276&rft_id=info:pmid/32362604&rft_galeid=A623244112&rfr_iscdi=true |